HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA To Prepare Guidance On Regulation Of Mental Health Apps

Executive Summary

The UK’s Medicines and Healthcare products Regulatory Agency will produce guidance determining which types of digital mental health tools should qualify as medical devices after receiving funding from charitable trust Wellcome.

You may also be interested in...



UK Recommends Digital Therapy App For Insomnia Sufferers

Big Health’s Sleepio app – which delivers cognitive behavioral therapy for insomnia – has been endorsed as an effective alternative to sleeping pills by the UK's National Institute for Health and Care Excellence.

Artificial Intelligence In Consumer Health: Reality, Challenge And Opportunity

Are self-care apps and digital health wearables touted as powered by AI actually "intelligent"? Currently, no. However, they could be in the future, if regulators can come up with frameworks flexible enough to keep up with adaptive algorithms and machine learning. This article looks at some of the key regulatory issues facing this fast-growing and exciting consumer health market. 

HBW Insight’s Key Takeaways From 2021: #3 Keep Your Eye On AI

The future of digital health will be shaped more than anything else by the rise of artificial intelligence. From body enhancing bio-wearables to camera-based skin diagnostics, the consumer health industry continued to explore the possibilities presented by AI in 2021. However, there are many regulatory and ethical hurdles industry must overcome as we move into 2022 and beyond.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS153015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel